Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

AARD vs LMNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AARD Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 6–2 Matrix Metrics)

AARD Overall Winner 6-Pillar Tally: AARD 4 – 0 LMNX (2 Tie) Matrix Metrics: AARD 6 – 2 LMNX

As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over LMNX (LMNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AARD carries a Unified Composite Score of 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin), whereas LMNX carries 53.5/100 (HOLD) at $9.16 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: AARD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7); meanwhile LMNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AARD vs LMNX
AARD NASDAQ Head-to-Head Winner
Aardvark Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$1.26
-5.26% 1D
Market Cap $29.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.10β · 288% Vol
Unified Composite Score
57.5 / 100 HOLD
Tech 79.0 Fund 63.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -33.9%), weak momentum, RSI 31
RSI-14: 30.7 · SMA20: $1.74 · SMA50: $3.68
LMNX US Equity
LMNX
Institutional Equity
$9.16
+0.6% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 4.92β · 98% Vol
Unified Composite Score
53.5 / 100 HOLD
Tech 63.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.3%), weak momentum, RSI 43
RSI-14: 43.2 · SMA20: $8.78 · SMA50: $12.88

6-Pillar Scorecard Institutional Category Breakdown (AARD 4 – 0 LMNX)

Columns: Metric · AARD · LMNX
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale AARD
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) N/A N/A
Market Cap $29.1M N/A
3. Profitability & Quality AARD
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -66.0% N/A
4. Balance Sheet & Cash Flow AARD
Cash Generation (TTM) -$69M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $73M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AARD
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 147.3% (26th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AARD (6) vs LMNX (2)
Institutional Metric AARD LMNX Criterion Row Edge
Market Capitalization
Scale
$29.1M N/A Larger Scale AARD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth AARD
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin AARD
Net Profit Margin
Profitability
0.0% N/A Higher Margin AARD
Return on Equity (ROE)
Capital Efficiency
-66.0% N/A Higher ROE AARD
52-Week Range Position
Momentum
2% ($1–$17) 5% ($7–$55) Stronger Trend LMNX
Beta / 30D Volatility
Risk Regime
4.10β · 288% Vol 4.92β · 98% Vol Lower Realized Risk LMNX
Unified Institutional Score
Composite Signal
57.5 / 100 (HOLD) 53.5 / 100 (HOLD) Higher Composite AARD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$69M ($73M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LMNX +0.96 pp
AARD: +24.44% · LMNX: +25.4%
3M Horizon AARD +91.69 pp
AARD: +57.62% · LMNX: -34.07%
6M Horizon LMNX +7.33 pp
AARD: -47.04% · LMNX: -39.71%
1Y Horizon AARD +31.25 pp
AARD: -39.04% · LMNX: -70.29%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AARD vs LMNX. Trailing 12-month operating profitability (AARD 0.0% vs LMNX N/A) and valuation multiples (AARD N/M vs LMNX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

AARD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-66.0% · N/M
LMNX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AARD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 147.3%
IV Percentile 26th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact AARD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LMNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LMNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AARD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $29.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LMNX Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AARD vs LMNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over LMNX (LMNX) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AARD carries a Unified Composite Score of 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin), whereas LMNX carries 53.5/100 (HOLD) at $9.16 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: AARD is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7); meanwhile LMNX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

AARD leads the Growth & Scale pillar: AARD posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with LMNX at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, AARD generates N/A in USD-normalized revenue versus N/A for LMNX. In operating R&D and SG&A reinvestment, AARD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LMNX.

AARD and LMNX trade at balanced relative valuation multiples. AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LMNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AARD (-66.0% ROE) versus LMNX (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 288% Vol realized risk). By comparison, LMNX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.92β · 98% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.